Cullen/Frost Bankers, Inc. Repligen Corp Transaction History

Cullen/Frost Bankers, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$119.79 - $167.35 $7,786 - $10,877	65 New	65 $9,000
Q4 2023 Feb 06, 2024	BUY	$114.17 - $185.35 $2,854 - $4,633	25 New	25 $4,000
Q1 2023 May 05, 2023	BUY	$154.26 - $198.1 $6,941 - $8,914	45 New	45 $7,000
Q2 2022 Aug 05, 2022	SELL	$140.68 - $188.02 $28,136 - $37,604	-200 Reduced 75.47%	65 $11,000
Q3 2021 Nov 04, 2021	SELL	$194.77 - $324.21 $38,954 - $64,841	-200 Reduced 43.01%	265 $77,000
Q1 2021 May 05, 2021	BUY	$180.37 - $226.26 $11,724 - $14,706	65 Added 16.25%	465 $90,000
Q3 2020 Nov 05, 2020	BUY	$122.51 - $158.27 $49,004 - $63,308	400 New	400 $59,000

479

54.9M

297K

343K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.15B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.